

PERSONAL INFORMATION

Iva Klarica Domjanovic

WORK EXPERIENCE

- December 2018- Present **Advisor for Non-Clinical and Clinical Assessment**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Assessment of PK studies in centralised procedures. - Assessment of bioequivalence studies and biowaivers in national, decentralised and centralised procedures.
- October 2016-December 2018 **Senior Associate Specialist for Non-clinical and Clinical documentation**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Assessment of bioequivalence studies and biowaivers in national and decentralised procedures.
- October 2014-October 2016 **Senior Associate for Regulatory Affairs**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Validation of applications for granting marketing authorization, renewal of marketing authorization and applications for variations.
- June 2012-October 2014 **Associate for Regulatory Affairs**
Agency for Medicinal Products and Medical Devices (HALMED) (Croatia)
- Validation of applications for granting marketing authorization, renewal of marketing authorization and applications for variations.
- January 2011-January 2012 **Community pharmacist**
Ljekarne zagrebake upanije (Croatia)
- Dispensing medicines, patient care, interaction checking, reports of adverse drug reactions

EDUCATION AND TRAINING

- September 2019- Present **MSc Model-based Drug Development**
The University of Manchester, Faculty of Biology, Medicine and Health, Division of Pharmacy and Optometry (United Kingdom)
- November 2011-May 2018 **Doctor of Philosophy (Ph.D.)**
University of Zagreb, Faculty of Science, Division of Biology, doctoral programme (Croatia)
- July 2005-October 2010 **Master of Pharmacy**
University of Zagreb, Faculty of Pharmacy and Biochemistry (Croatia)

ADDITIONAL INFORMATION

- Expertise** Pharmacogenomics, pharmacokinetics
- Publications** - Krasniqi V, Dimovski A, Domjanovi IK, Bili I, Boina N (2016) How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arh Hig

Rada Toksikol 67(1): 1-8. - Boina N, Klarica Domjanovi I, Ganoci L (2017) Farmakogenomika u pedijatrijskoj populaciji. Paediatr Croat 61 (Supl 1): 184-192. - Lovri M, aji I, Petelin Gade , Klarica Domjanovi I, Boina N (2018) Effect of antiepileptic drug comedication on lamotrigine concentrations. Croat Med J 59(1): 13-19. - Klarica Domjanovi I, Lovri M, Trkulja V, Petelin-Gade , Ganoci L, aji I, Boina N. (2018) Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol. 84(9):2106-2119. - Boina N, Spori I, Boina T, Klarica-Domjanovi I, Tvrdei A, Spori D (2019) Pharmacogenetics and the treatment of epilepsy: what do we know?. Pharmacogenomics. 20(15):1093-1101. doi: 10.2217/pgs-2019-0085 Published congress abstracts: - Bozina N, Mirosevic Skvrce N, Ganoci L, Mas P, Klarica Domjanovic I, Simic I (2016) Integrating Pharmacovigilance and Pharmacogenomics: Croatian Experience. Clin Ther 6;38(10S):e23 - Ganoci L, Lovri M, Ivkovi M, Agud M, Klarica Domjanovi I, Boina N (2016) The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone. Clin Ther 6;38(10S): e10-e11
 - Domjanovic I.K., Skvrce N.M., Bilusic A.B., Ganoci L., Bozina N., Sertic D (2018) Pharmacogenetic Markers of Adverse Reactions of Tyrosine Kinase Inhibitors Case Report. Abstracts from First Nordic conference on personalized medicine 2018 in Nyborg, Denmark. Basic Clin Pharmacol Toxicol, 123: 3-14. doi:10.1111/bcpt.13020

Projects

Memberships

- Member of Croatian Chamber of Pharmacists- Croatian Society of Pharmacogenomics

Other Relevant Information